Craigavon-based pharmaceutical firm Almac will be setting up new offices in the IDA Business Park here in Dundalk with up to 100 jobs announced.
Margaret Canning, Belfast Telegraph Business Editor reports that, IDA chief Martin Shanahan says the Almac move to Dundalk signals how important Ireland's access to single market will be as a selling point.
Almac will make a multimillion euro investment in the new facility at IDA Business Park. The expansion has been supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland, Ireland’s inward investment promotion agency.
Alan Armstrong, CEO Almac Group commented: “This latest investment in Dundalk is a further example of Almac’s ambitious global expansion plans and will deliver up to an additional 100 new jobs within the first two years. This news comes in addition to our recent announcement of a £27m investment at our global Headquarter site in Craigavon, our US operations and our European facility in Athlone. All of this is evidence of Almac’s commitment to provide best-in-class products and services to our clients across the world and we would like to thank all those who have supported us to date.”
Welcoming the investment by Almac, Minister for Jobs, Enterprise and Innovation, Mary Mitchell O’Connor said: “This is a very exciting project for Dundalk and builds on the strong cluster of multinational companies who have very successfully located in that town in recent years and who have found it a great base from which to promote their sales into other EU Member States. Ireland’s expertise in the Pharma sector is unrivalled, with virtually all the major international players having operations here, thus generating synergies and opportunities for new companies investing with us. These additional 100 jobs to be provided are very welcome and we look forward to a long and mutually beneficial engagement with Almac into the future”.
Martin Shanahan, CEO, IDA Ireland said “Almac’s decision to expand into Dundalk provides the company with certainty of access to the European Union in the long term– this certainty of access is an increasingly important selling point for Ireland as we look to win business for Ireland. IDA Ireland will continue to promote Ireland as an ideal location for companies from a range of sectors including pharmaceuticals, IT and financial services that are looking to ensure that they have a presence in the European single market.”
This investment strengthens Almac’s existing presence in the Republic of Ireland following the acquisition of Arran Chemical Company facility in Athlone in 2015. The facility has expanded the company’s biocatalysis services, which is part of Almac’s Sciences Business Unit.
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services globally to companies within the pharmaceutical and biotech sectors.
The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS technology(IVRS/IXRS) through to commercial-scale manufacture and companion diagnostic development.